Effect of DC-CIK Cells' Biotherapy in Comprehensive Therapy of Esophagus Cancer: A Randomized Controlled Trial_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

XIXiao-xiang ¹ ,  LVBi-hong ¹ , YETing ² , CHENRui ¹ , XUXiang ¹

1. Department of Thoracic Surgery, Taixing People's Hospital, The Affiliated Hospital of Medical School of Yangzhou University, Taixing 225400 Jiangshu, P. R. China;
2. Department of Clinical Laboratory, Taixing People's Hospital, The Affiliated Hospital of Medical School of Yangzhou University, Taixing 225400 Jiangshu, P. R. China;

Corresponding author：

LVBi-hong, Email: ZXXXX7576@163.com

Keywords：

DC-CIK; Esophagus cancer; Therapy

DOI：

10.7507/1007-4848.20150191

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the short-term curative efficacy of DC-CIK in comprehensive therapy of esophagus cancer. Methods We randomly allocated 52 patients with esophagus cancer who had preoperatively confirmed by CT on stage Ⅱ-Ⅲ B into an observation group and a control group with 26 patients in each group. There were 14 male and 12 female patients in the observation group at median age of 60 years (range:49-67 years). There were 16 male and 10 female patients in the control group with median age of 62 years (range:48-65 years).The control group received postoperative chemotherapy, and the observation group received postoperative chemotherapy combined with DC-CIK biotherapy. The combination of paclitaxel and cisplatin for four cycles was choosen as the chemotherapy regimen. Patients in the observation group were treated with DC-CIK biotherapy for 2 weeks after operation. At the fifth week they received the first cycle of chemotherapy. There was a course of biotherapy between two cycles of chemotherapy. The clinical efficacy, lymphocyte subtypes, and intracellular cytokines in peripheral blood of the patients, performance status (KPS) and adverse reactions were compared. Results All patients completed the therapy regimen successfully. In the observation group, the ratios of CD3⁺, CD4⁺, CD4⁺/CD8⁺, CD56⁺, and CD19⁺ increased, and the ratio of CD8⁺ decreased with significant differences (P<0.05).The biotherapy significantly increased interleukin 2 (IL-2), IL-12, interferon gamma (IFN-γ) and tumor necrosis fator (TNF)-α level (P<0.05). However, in the control group, there was no significant difference between post and pre-therapy in the levels of lymphocytes and cytokines. The effective rate of KPS was 76.92% in the observation group and 46.15% in the control group with a significant difference (P=0.023). No other adverse reactions except 3 patients with fever in the observation group were found. Conclusion The short-term curative efficacy of DC-CIK in comprehensive therapy of esophagus cancer is distinct. DC-CIK biotherapy can improve patients' immune functions and elevate their life quality, so it is likely to be an effective adoptive immunotherapy for esophagus cancer.

Citation： XIXiao-xiang, LVBi-hong, YETing, CHENRui, XUXiang. Effect of DC-CIK Cells' Biotherapy in Comprehensive Therapy of Esophagus Cancer: A Randomized Controlled Trial. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2015, 22(8): 765-769. doi: 10.7507/1007-4848.20150191 Copy

1.	史菊, 缪竞诚, 顾国浩. 食管癌组织和外周血miRNA检测技术及其应用的研究进展.检验医学与临床, 2012, 9(21):2729-2731.
2.	张卓. 同期放化疗治疗食管癌的研究进展. 临床医药实践, 2014, 23(1):50-53.
3.	黄孙卉, 张崇友, 王志华. DC与CIK细胞共培养在肿瘤治疗中的研究进展. 实用肿瘤学杂志, 2011, 25(1):14-17.
4.	唐安球, 周华富. 食管癌治疗现状及进展. 医学综述, 2014, 20(1):39-41.
5.	张彤, 王佩, 张振海. 紫杉醇顺铂方案联合自体 CIK细胞输注治疗晚期食道癌的临床分析. 中国免疫学杂志, 2012, 28(7):652-656.
6.	陈诗萍, 买世娟, 余杏娟, 等. 树突状细胞诱导的CIK细胞对肺癌生长的抑制作用. 中国医药生物技术, 2012, 7(2):125-129.
7.	郝世凯, 苏相相, 王丹丹, 等. 树突状细胞联合细胞因子诱导的杀伤细胞在肿瘤过继免疫治疗中的研究进展. 医药前沿, 2014, 21:185-187.
8.	叶联华, 黄云超, 赵光强, 等.细胞因子诱导的杀伤细胞免疫治疗对非小细胞肺癌患者术后免疫功能的影响. 中国胸心血管外科临床杂志, 2008, 15(2):96-100.
9.	刘苗, 姜毅. DC-CIK细胞治疗的生物学基础与临床应用. 河北医药, 2010, 32(24):3535-3537.
10.	Jiang JT, Shen YP, Wu CP, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.World J Gastroenterol, 2010, 16(48):6155-6162.
11.	陈冬波, 张世强, 王保庆, 等. 树突状细胞与细胞因子诱导的杀伤细胞免疫治疗对恶性肿瘤化疗后患者免疫功能的影响. 国际检验医学杂志, 2011, 32(5):571-575.
12.	朱月华, 刘军权, 曹卉, 等. 放疗联合自身免疫细胞治疗宫颈癌的临床疗效. 中国肿瘤生物治疗杂志, 2012, 19(04):421-427.
13.	张晓冬, 郭明浩, 常占国, 等. DC、CIK 自体回输对化疗后胃癌患者 T 淋巴细胞亚群及 NK细胞的影响. 山东医药, 2014, 54(3):70-72.
14.	崔建东, 彭清云, 李涛, 等. 放化疗联合 DC-CIK治疗脑胶质瘤复发 40例的临床观察. 现代生物医学进展, 2013, 13(20):3860-3862.
15.	齐欣, 张玉田, 吴晨, 等. DC-CIK配合中药治疗化疗无效晚期恶性肿瘤患者的护理体会. 中外医学研究, 2013, 11:66-67.
16.	Zhou P, Liang P, Dong B, et al. Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther, 2011, 11(5):450-456.
17.	夏禾爱, 郝建峰, 陈玲, 等. DC-CIK细胞的制备及其对恶性肿瘤的疗效观察. 现代肿瘤医学, 2013, 21(10):2194-2197.
18.	庞佳楠, 崔久嵬.细胞因子诱导的杀伤细胞治疗肿瘤的研究进展. 中华临床医师杂志:电子版, 2014, 8(15):2889-2893.
19.	宋庆林, 夏瑞雪. DC-CIK 方案治疗41例急性白血病清除微小残留病变的疗效. 中国实用医刊, 2014, 41(11):32-34.
20.	汪舸, 闵海燕, 张航, 等. CIK细胞治疗对肿瘤晚期患者外周血中免疫细胞及细胞因子的影响. 实用临床医药杂志, 2011, 15(5):95-96.
21.	李新迪, 孟凡旭, 王欣, 等. DC-CIK细胞免疫疗法对卵巢癌患者免疫功能的影响及临床意义. 中国实验诊断学, 2014, 18(2):283-286.
22.	蔡俊霞, 谭洁, 王彬, 等. DC-CIK治疗43例晚期非小细胞肺癌的近期疗效观察. 现代肿瘤医学, 2014, 22(1):67-70.
23.	张晓雪, 毛志福, 林道明. T 辅助细胞分泌的细胞因子在食管鳞癌组织中的表达及其临床意义. 中国胸心血管外科临床杂志,2005, 12(3):169-172.
24.	陈倩倩, 黎菲菲, 曾今诚, 等. IL-12 家族抗肿瘤作用的研究进展.国际检验医学杂志, 2014, 35(11):1453-1455.
25.	王颖, 吴德平, 明平静, 等. DC与CIK共培养细胞体外抗肝癌细胞活性研究. 中华微生物学和免疫学杂志, 2014, 34(1):42-46.
26.	Miwa S, Nishida H, Tanzawa Y, et al. TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumor. PLos One, 2012, 7(12):e52926.

1. 史菊, 缪竞诚, 顾国浩. 食管癌组织和外周血miRNA检测技术及其应用的研究进展.检验医学与临床, 2012, 9(21):2729-2731.
2. 张卓. 同期放化疗治疗食管癌的研究进展. 临床医药实践, 2014, 23(1):50-53.
3. 黄孙卉, 张崇友, 王志华. DC与CIK细胞共培养在肿瘤治疗中的研究进展. 实用肿瘤学杂志, 2011, 25(1):14-17.
4. 唐安球, 周华富. 食管癌治疗现状及进展. 医学综述, 2014, 20(1):39-41.
5. 张彤, 王佩, 张振海. 紫杉醇顺铂方案联合自体 CIK细胞输注治疗晚期食道癌的临床分析. 中国免疫学杂志, 2012, 28(7):652-656.
6. 陈诗萍, 买世娟, 余杏娟, 等. 树突状细胞诱导的CIK细胞对肺癌生长的抑制作用. 中国医药生物技术, 2012, 7(2):125-129.
7. 郝世凯, 苏相相, 王丹丹, 等. 树突状细胞联合细胞因子诱导的杀伤细胞在肿瘤过继免疫治疗中的研究进展. 医药前沿, 2014, 21:185-187.
8. 叶联华, 黄云超, 赵光强, 等.细胞因子诱导的杀伤细胞免疫治疗对非小细胞肺癌患者术后免疫功能的影响. 中国胸心血管外科临床杂志, 2008, 15(2):96-100.
9. 刘苗, 姜毅. DC-CIK细胞治疗的生物学基础与临床应用. 河北医药, 2010, 32(24):3535-3537.
10. Jiang JT, Shen YP, Wu CP, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.World J Gastroenterol, 2010, 16(48):6155-6162.
11. 陈冬波, 张世强, 王保庆, 等. 树突状细胞与细胞因子诱导的杀伤细胞免疫治疗对恶性肿瘤化疗后患者免疫功能的影响. 国际检验医学杂志, 2011, 32(5):571-575.
12. 朱月华, 刘军权, 曹卉, 等. 放疗联合自身免疫细胞治疗宫颈癌的临床疗效. 中国肿瘤生物治疗杂志, 2012, 19(04):421-427.
13. 张晓冬, 郭明浩, 常占国, 等. DC、CIK 自体回输对化疗后胃癌患者 T 淋巴细胞亚群及 NK细胞的影响. 山东医药, 2014, 54(3):70-72.
14. 崔建东, 彭清云, 李涛, 等. 放化疗联合 DC-CIK治疗脑胶质瘤复发 40例的临床观察. 现代生物医学进展, 2013, 13(20):3860-3862.
15. 齐欣, 张玉田, 吴晨, 等. DC-CIK配合中药治疗化疗无效晚期恶性肿瘤患者的护理体会. 中外医学研究, 2013, 11:66-67.
16. Zhou P, Liang P, Dong B, et al. Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther, 2011, 11(5):450-456.
17. 夏禾爱, 郝建峰, 陈玲, 等. DC-CIK细胞的制备及其对恶性肿瘤的疗效观察. 现代肿瘤医学, 2013, 21(10):2194-2197.
18. 庞佳楠, 崔久嵬.细胞因子诱导的杀伤细胞治疗肿瘤的研究进展. 中华临床医师杂志:电子版, 2014, 8(15):2889-2893.
19. 宋庆林, 夏瑞雪. DC-CIK 方案治疗41例急性白血病清除微小残留病变的疗效. 中国实用医刊, 2014, 41(11):32-34.
20. 汪舸, 闵海燕, 张航, 等. CIK细胞治疗对肿瘤晚期患者外周血中免疫细胞及细胞因子的影响. 实用临床医药杂志, 2011, 15(5):95-96.
21. 李新迪, 孟凡旭, 王欣, 等. DC-CIK细胞免疫疗法对卵巢癌患者免疫功能的影响及临床意义. 中国实验诊断学, 2014, 18(2):283-286.
22. 蔡俊霞, 谭洁, 王彬, 等. DC-CIK治疗43例晚期非小细胞肺癌的近期疗效观察. 现代肿瘤医学, 2014, 22(1):67-70.
23. 张晓雪, 毛志福, 林道明. T 辅助细胞分泌的细胞因子在食管鳞癌组织中的表达及其临床意义. 中国胸心血管外科临床杂志,2005, 12(3):169-172.
24. 陈倩倩, 黎菲菲, 曾今诚, 等. IL-12 家族抗肿瘤作用的研究进展.国际检验医学杂志, 2014, 35(11):1453-1455.
25. 王颖, 吴德平, 明平静, 等. DC与CIK共培养细胞体外抗肝癌细胞活性研究. 中华微生物学和免疫学杂志, 2014, 34(1):42-46.
26. Miwa S, Nishida H, Tanzawa Y, et al. TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumor. PLos One, 2012, 7(12):e52926.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Effect of DC-CIK Cells' Biotherapy in Comprehensive Therapy of Esophagus Cancer: A Randomized Controlled Trial

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content